Announcement PDF ASX ANNOUNCEMENT CEO CONTRACT MELBOURNE (AUSTRALIA) 9 JULY 2021: Invion Limited (ASX: IVX) (Invion or the Company) is pleased to announce that it has entered into the following employment agreement with CEO, Thian Chew. Position Chair and CEO Effective Date 1 November 2020 (being the date of commencement of CEO role) CEO Base Salary AUD$309,000 applicable) Chair Base Salary AUD$90,000 per annum (including superannuation if applicable) Short Term Incentive Annual incentive of a maximum of 50% of CEO Base Salary based on set annual targets. Long Term Incentive Equal to 2.5% equity in the form of premium priced options. (subject approval) to per annum (including superannuation shareholder The options will have a nil issue price. The exercise price will be $0.017. Options will vest on the following dates and in the following proportions, subject to the rules relating to forfeiture in the Employee Option Plan: On grant date: (25% of Options vest) 1 November 2021: (25% of Options vest) 1 November 2022: (25% of Options vest) 1 November 2023: (25% of Options vest) Term of Contract The Options expire 4 years after the grant date. Ongoing Termination with notice 6 months’ notice by each party ____________________________________________ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 8618 6843 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon@vantagepointpartners.com.au Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com if About Invion Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited and its affiliates, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by the Board of Directors. For further information please contact Investor@inviongroup.com). About Photodynamic Therapy (PDT) Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes. Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com